The company's Phase 2 BESTOW trial results showed tegoprubart reduces the metabolic, neurologic and cardiovascular toxicities commonly associated with tacrolimus, positioning it as a potential safer alternative to standard-of-care immunosuppression. Eledon is advancing tegoprubart's programs in kidney transplantation, islet cell transplantation, and xenotransplantation, with Phase 3 development targeted for 2026.
Cyborg Score Rationale
Analyst sentiment is positive with a "Strong Buy" rating and 12-month price target of $8.5, representing 441% upside potential. The company has demonstrated promising clinical data and multiple programs advancing through development, though early-stage biotech status presents execution risks.
Top Insights
Phase 2 BESTOW trial demonstrated superior safety profile with substantially reduced cardiovascular, metabolic, and neurologic toxicities versus standard tacrolimus-based regimens
Diversified clinical pipeline across kidney transplantation, islet cell transplantation, xenotransplantation, and ALS creates multiple value inflection points
Strategic collaboration with eGenesis positions company at forefront of xenotransplantation advancement (genetically modified pig kidney transplants)
Pre-Phase 3 stage means significant value creation potential upon positive regulatory feedback, though capital requirements remain substantial
Named Competitors
Calcineurin Inhibitors (Tacrolimus/FK506) — Current standard-of-care immunosuppression with significant toxicity burden
mTOR Inhibitors — Alternative immunosuppression class